Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$251.56
+0.4%
$235.85
$211.43
$387.99
$6.85B0.95394,398 shs109,086 shs
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
$14.00
$437.29MN/A503,865 shsN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$16.12
-2.3%
$16.86
$13.61
$30.36
$5.44BN/A28,587 shs31,814 shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.00%+3.10%+14.63%+11.70%-6.85%
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%+0.77%-7.12%+18.47%+1,612,399,900.00%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.8672 of 5 stars
3.45.00.04.23.12.51.9
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.75
Moderate Buy$324.2528.90% Upside
Pfenex Inc. stock logo
PFNX
Pfenex
0.00
N/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
3.00
Buy$22.3338.51% Upside
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PFNX, TLX, SPL, BIO, and TRIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$23.00
6/12/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$22.00
6/9/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $245.00
6/5/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
5/2/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$355.00 ➝ $310.00
5/2/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$400.00 ➝ $350.00
5/2/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$409.00 ➝ $392.00
4/17/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$320.00 ➝ $270.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.57B2.67$10.39 per share24.21$234.52 per share1.07
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$516.72M10.56$0.11 per share140.73$1.12 per share14.40
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$1.84B-$76.20N/A20.21N/A-85.16%4.32%3.03%7/30/2025 (Estimated)
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/A0.00N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$32.93MN/A0.0033.59N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest PFNX, TLX, SPL, BIO, and TRIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$1.73$2.54+$0.81$2.29$573.01 million$585.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.18
5.99
4.43
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.99
2.78
2.66
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82

Institutional Ownership

CompanyInstitutional Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
87.15%

Insider Ownership

CompanyInsider Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.06%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
7,70027.21 million22.57 millionOptionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A338.38 millionN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

Recent News About These Companies

Trillium Therapeutics Stock Price History
TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal
Advances in Drug Discovery & Development 2024
Cachet Bicycle shakes off COVID
BridgeBio raises $1.25bn, and other biotech financings
Ratio Therapeutics Raises $50M in Series B Financing
Leukemia Therapeutics Global Market Report 2023

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bio-Rad Laboratories stock logo

Bio-Rad Laboratories NYSE:BIO

$251.56 +0.91 (+0.36%)
As of 07/3/2025 03:30 PM Eastern

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Pfenex stock logo

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)
As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$16.12 -0.38 (-2.28%)
As of 07/3/2025 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Trillium Therapeutics stock logo

Trillium Therapeutics NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.